Cannabinoids are a rapidly evolving area of medical science and understanding them can feel overwhelming. This series, brought to you by the Child Neurology Foundation, and sponsored by Jazz Pharmaceuticals, breaks down the essentials for families, caregivers, and healthcare providers.
Through three episodes, our experts provide clear, evidence-based guidance on cannabinoids, clinical considerations, and policy to help you make informed decisions.
Episode 1: Understanding Cannabinoids – 5 Things to Know
Dr. Jennifer Triemstra introduces the fundamentals of cannabinoids. This episode covers five key areas:
- Terminology: Understanding the difference between cannabis (the plant) and cannabinoids (the active molecules).
- Cannabinoid Classes: Endocannabinoids (produced in the body), Phytocannabinoids (plant-derived), and synthetic cannabinoids.
- Cannabis Products: Medical vs. recreational cannabis, hemp products, and FDA-approved cannabinoid medicines.
- Legal & Regulatory Considerations: The variability of state regulations and the risks of unregulated products, including inconsistent potency and contamination.
- Continuing Education: How to seek reliable, evidence-based cannabinoid information.

“Keep yourself educated, ask where the evidence is, and develop an evidence-based approach to cannabinoids. This empowers you to make informed decisions for yourself and your loved ones.” – Dr. Jennifer Triemstra
Episode 2: Understanding Cannabinoids – How to Start the Conversation with Your Child’s Provider

At the heart of the episode is the importance of simply starting the conversation. As Dr. Gidal explains:
“We have conditioned people to think when they bring up ‘cannabis’ or ‘CBD’ that it’s a drug of abuse, instead of a medicine. Cannabinoids are medicine. So, what I encourage people to do is just talk to me. Tell me what you’re thinking, tell me what you’ve heard, and then let me respond and tell you what I think. That’s the biggest roadblock- getting that conversation started and patients and families feeling comfortable enough to do so with their provider.”
Families often feel unsure about how to talk with their medical professionals about cannabinoids, particularly due to stigma and shifting laws across states. In this episode, Dr. Barry Gidal and Dr. Jason Vinson discuss why open, honest communication is essential for safe and informed care.
They explore what questions families can ask, what information healthcare professionals need to know, and how both sides can work together when considering cannabinoid-based therapies. The conversation also highlights differences in product quality, state regulations, potential side effects, and why clear documentation — like seizure diaries — can help the care team make thoughtful decisions.
Additional Guides:
Episode 3: Understanding Cannabinoids – What Families Should Know About Safety and Regulation
Dr. Jennifer Triemstra and Daniela Sharfstein of Jazz Pharmaceuticals explain how cannabinoids are regulated in the U.S. This episode focuses on:
- Federal and state regulations, including the 2014 and 2018 Farm Bills
- The patchwork of state-level medical cannabis programs
- Risks in the unregulated hemp and CBD marketplace
- FDA-approved medicines vs. over-the-counter products
- The importance of differentiating between consumer products and prescribed medicines

About This Series
This educational series was made possible through the Child Neurology Foundation, sponsored by Jazz Pharmaceuticals. Our goal is to empower families and healthcare providers with trustworthy, evidence-based cannabinoid education.
Learn More and Stay Informed:
- Child Neurology Foundation Resources
- Cannabinoid Clinical Education
- FDA Guidance on Cannabis and CBD



